Study guide

7.2 Genetics and Genomics

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

7.2 Genetics and Genomics

Key Takeaways Explain This Topic AI

Somatic findings live in the tumor clone and guide diagnosis, risk, and targeted therapy; germline variants are in every cell and confer predisposition plus family implications.

Flag Li-Fraumeni (TP53), RB1, WT1/WAGR, Beckwith-Wiedemann, NF1, Down syndrome (TAM, ALL, AML), Fanconi anemia, DICER1, and SMARCB1 rhabdoid predisposition for counseling.

Refer genetic counseling for bilateral or multifocal disease, unusual age, associated anomalies, or a family history of early, multiple, or rare cancers.

TPMT or NUDT15 deficiency can cause life-threatening myelosuppression from usual mercaptopurine doses; use protocol-based reductions rather than a memorized star-allele table.

Cytogenetics, FISH, and NGS refine risk and can add targeted therapy—imatinib or another protocol TKI for BCR-ABL1 ALL—while germline testing in minors needs parental permission, assent, and confidentiality.

Last updated: August 2026

Genetics on CPHON is not a recitation of every fusion ever published. TCO II.A.3 asks whether you can tell a somatic tumor finding from a germline predisposition, when to pick up the phone for genetic counseling, why mercaptopurine can flatten a child's counts if TPMT or NUDT15 is deficient, and how cytogenetics, FISH, and sequencing change risk and add a targeted drug. The named rearrangements— MYCN , BCR-ABL1 , PML-RARA , EWSR1 , FOXO1 —already appear in disease chapters. Here you learn the how , not a new laundry list.

Somatic versus germline

A somatic mutation or fusion lives in the tumor (or the leukemic clone). It is not in the child's egg or sperm cells and is not passed to future children. BCR-ABL1 in Ph-positive ALL is a somatic leukemia finding. EWSR1-FLI1 in Ewing sarcoma is a somatic diagnostic fusion. A germline variant is present in essentially every cell, including the germline, and can be inherited or arise de novo. Germline variants explain cancer predisposition syndromes , sibling risk, and sometimes a different surveillance or radiation plan. The same gene can appear in both stories: a somatic TP53 mutation in a tumor is not automatically Li-Fraumeni syndrome; germline TP53 testing is a separate question with family implications.

Teach families the difference in one sentence. This result tells us how to treat this cancer, versus this result tells us whether your child's body was born with a higher cancer risk and whether relatives need counseling. Mixing those sentences is how a parent hears that every sibling must start chemotherapy.

Predisposition syndromes you should be able to flag

You are not the geneticist. You are the nurse who notices bilateral disease, an odd age, an associated anomaly, or a family history and does not let the consult wait until after maintenance.

Li-Fraumeni syndrome (TP53) : sarcomas, osteosarcoma, CNS tumors, adrenocortical carcinoma, and early-onset breast cancer in the family. Avoid unnecessary radiation when an effective alternative exists; the child and relatives need formal counseling.

Heritable retinoblastoma (RB1) : bilateral or multifocal disease is germline until proven otherwise, even with a negative family history, because many RB1 variants are de novo. Later osteosarcoma and soft-tissue sarcoma risk belongs in survivorship teaching.

WT1-related and overgrowth renal risk : WAGR (Wilms tumor, aniridia, genitourinary anomalies, range of developmental delay), Denys-Drash, and Beckwith-Wiedemann syndrome (BWS) change screening—serial abdominal ultrasound, and AFP as the hepatoblastoma program specifies for BWS—not a wait-for-a-visible-mass plan. BWS is an imprinting/overgrowth syndrome (11p15), not a WT1 deletion; the shared nursing action is still ultrasound screening.

Neurofibromatosis type 1 (NF1) : café-au-lait macules, optic pathway glioma, later malignant peripheral nerve-sheath tumor. Vision checks are not optional trivia.

Down syndrome (trisomy 21) : transient abnormal myelopoiesis (TAM) in neonates; later ALL and myeloid leukemia of Down syndrome. Not every neonate with blasts is transplanted on day 2; not every toddler with Down syndrome and cytopenias has a virus.

Fanconi anemia : marrow failure, AML, and solid tumors, plus marked sensitivity to DNA-crosslinking chemotherapy. Dose modification is a protocol decision; full unmodified alkylator intensity is not a nursing improvisation.

DICER1 syndrome : pleuropulmonary blastoma, ovarian Sertoli-Leydig tumor, multinodular goiter, cystic nephroma. A young child with a lung cyst plus a family thyroid story is not just a pneumonia cavity.

Rhabdoid tumor predisposition (SMARCB1) : atypical teratoid/rhabdoid tumor and renal rhabdoid disease in very young children. Brain imaging belongs in the renal-rhabdoid workup.

  • Finding Typical gene or mechanism Why the nurse refers
  • Bilateral or multifocal retinoblastoma RB1 germline Counseling even if family history is negative
  • Soft-tissue sarcoma plus a parent with early breast cancer TP53 (Li-Fraumeni) Family risk; radiation decisions
  • Aniridia or hemihypertrophy plus a renal mass WT1 / WAGR / BWS Contralateral kidney and screening ultrasounds
  • Café-au-lait macules and declining vision NF1 Optic pathway glioma pathway
  • Neonate with Down syndrome and blasts Trisomy 21 TAM versus later myeloid leukemia
  • Infant renal mass plus a CNS lesion SMARCB1 Rhabdoid predisposition, not Wilms with a separate stroke
  • When to refer genetic counseling

Refer when disease is bilateral or multifocal , occurs at an unusual age , comes with congenital anomalies , or sits in a family history of early, multiple, or rare cancers. A 14-month-old with bilateral retinoblastoma does not wait for three generations of pedigrees. A 3-year-old with Wilms tumor and aniridia already has a counseling indication. A teenager with osteosarcoma and a parent who died of a brain tumor at 31 is Li-Fraumeni until counseling says otherwise. Document the referral. Do not promise a negative test as a cure.

Pharmacogenomics: TPMT, NUDT15, and thiopurines

Mercaptopurine (6-MP) and thioguanine are backbone thiopurines in ALL maintenance and some AML pathways. TPMT and NUDT15 enzymes help inactivate thiopurine metabolites. Children with deficient activity accumulate active thioguanine nucleotides in marrow and can develop life-threatening myelosuppression at usual milligram-per-square-meter doses. Protocols use genotype or activity to guide dose reductions. Do not memorize a star-allele table as an ONCC fact; allele nomenclature changes and is not the scored point. The scored point is: unexplained, profound neutropenia or pancytopenia after mercaptopurine is a pharmacogenomic emergency, not nonadherence until proven guilty, and you do not restart full-dose 6-MP because the child looks well today.

A 5-year-old in ALL maintenance whose ANC crashes after the first weeks of mercaptopurine needs a hold, an infection workup, and a TPMT/NUDT15 pathway review with the protocol team—not a lecture about hiding pills. Conversely, a child with known deficiency still receives thiopurines on many protocols, just at a reduced, protocol-specified dose . Deficiency is not a reason to invent a homemade regimen.

How cytogenetics, FISH, and NGS change risk and therapy

Karyotype (conventional cytogenetics) sees chromosome number and many large rearrangements; it takes days. FISH uses a fluorescent probe for a known target (BCR-ABL1, KMT2A, EWSR1, PML-RARA) and returns faster. NGS panels and RNA fusion assays find cryptic fusions and mutations karyotype can miss. None of these replace morphology and flow on day 0, and none return in an hour.

Teach how the result is used, using names families already hear in disease chapters:

BCR-ABL1 (Philadelphia chromosome) in ALL does not change the fact that this is ALL; it adds a tyrosine kinase inhibitor (TKI) such as imatinib (or another protocol TKI) to the backbone and changes risk assignment.

PML-RARA defines APL and redirects therapy to tretinoin and arsenic trioxide because coagulopathy, not an asparaginase induction, is the emergency.

MYCN amplification in neuroblastoma is a biologic risk factor that helps place the child in a high-risk group; it is not a bedside vital sign.

EWSR1 rearrangement confirms Ewing family sarcoma when morphology is a small-round-blue-cell tumor; it is why Ewing is not osteosarcoma in a younger child.

FOXO1 fusion in rhabdomyosarcoma supports alveolar biology and a higher-risk conversation; fusion-negative disease is often closer to embryonal risk.

Initial chemotherapy starts on clinical diagnosis. Genetics then refine intensity and add targeted agents. That is why families hear that treatment started while cytogenetics are still pending.

Confidentiality, assent, and consent for genetic testing in minors

Somatic tumor testing is part of cancer diagnosis; explain it as disease characterization. Germline testing is different. A parent or legal guardian gives permission . A developmentally able child or adolescent gives assent . You do not coerce a 16-year-old into a predisposition panel by saying the port will be pulled if they refuse. Results may reveal misattributed parentage, unexpected carrier status, or a parent's own cancer risk. Share results along the agreed family plan, in private, and do not post genotypes on the hallway whiteboard. Siblings are not automatically tested without their own consent process. A 12-year-old can understand that one test looks at the cancer cells and another looks at the genes they were born with and might tell us about brothers or sisters. Keep those conversations separate.

The CPHON product is a nurse who flags bilateral disease, holds mercaptopurine when a deficient metabolizer is crashing, explains why imatinib appears on a Ph-positive ALL roadmap, and never treats a germline report as hallway gossip.

Loading diagram... Somatic results, germline counseling, and thiopurine safety